Poincloux L, Goutorbe F, Rouquette O, Mulliez A, Goutte M, Bommelaer G, Abergel A
Digestive Diseases Department, NHE University Hospital of Clermont-Ferrand, 63003, Clermont-Ferrand, France.
ISIT (Image Sciences for Innovations Techniques), UMR Auvergne University/CNRS 6284, Clermont-Ferrand, France.
Surg Endosc. 2016 Feb;30(2):437-445. doi: 10.1007/s00464-015-4216-8. Epub 2015 Apr 17.
Duodenal covered self-expandable metal stent (cSEMS) can be used in malignant or benign gastroduodenal obstruction. The need for biliary stenting in patients with no concomitant biliary stricture, before duodenal cSEMS placement, remains unknown. The aim of this study was to determine whether cSEMS placement is responsible for biliary obstruction.
This is a single-center, retrospective, case-controlled study, including 106 patients with symptomatic gastric outlet obstruction or duodenal fistula who received a covered nitinol duodenal stent by using through-the-scope/over-the-wire placement procedure. The main outcome measurement was the occurrence comparison of jaundice and bilirubin level, between patients with previous or concomitant biliary stenting (cSEMS + BS group), and patients with no biliary stent (cSEMS group) during an observational period of 90 days.
Hundred and six patients underwent cSEMS placement between June 2005 and March 2014: 53 in the cSEMS group (58% male, mean age 66.4 ± 13.3 years) and 53 in cSEMS + BS group (60% male, mean age 70.4 ± 11.6 years). The obstruction was due to cancer in 45% in cSEMS group and 87% in cSEMS + BS group. No case of jaundice was reported in the cSEMS group or in the cSEMS + BS group. In cSEMS group, the mean bilirubin level (μmol/L ± SD) was 8.0 ± 4 at baseline and 8.5 ± 4.6 at day 10, while in the cSEMS + BS group it was 91.4 ± 108 at baseline and 35.3 ± 39 at day 10 (p < 0.01). Patients from the two groups were matched on age, gender and bilirubin level at baseline. Evolution of bilirubinemia was +0.98 ± 2.76 µmol/L in experimental group and +0.39 ± 522 µmol/L in the control group (p = 0.34). No significant difference was observed between the two groups in term of technical success, clinical effectiveness, migration and other complications.
Previous biliary stenting is not required before endoscopic covered duodenal stent placement in patients with no associated biliary obstruction. Prospective studies are needed.
十二指肠覆膜自膨式金属支架(cSEMS)可用于恶性或良性胃十二指肠梗阻。对于在放置十二指肠cSEMS之前没有合并胆道狭窄的患者是否需要进行胆道支架置入尚不清楚。本研究的目的是确定放置cSEMS是否会导致胆道梗阻。
这是一项单中心、回顾性、病例对照研究,纳入106例有症状的胃出口梗阻或十二指肠瘘患者,这些患者通过经内镜/导丝置入法接受了镍钛合金覆膜十二指肠支架。主要观察指标是比较在90天观察期内,既往或合并胆道支架置入的患者(cSEMS+BS组)与未置入胆道支架的患者(cSEMS组)黄疸和胆红素水平的发生情况。
2005年6月至2014年3月期间,106例患者接受了cSEMS置入:cSEMS组53例(男性58%,平均年龄66.4±13.3岁),cSEMS+BS组53例(男性60%,平均年龄70.4±11.6岁)。cSEMS组45%的梗阻是由癌症引起,cSEMS+BS组为87%。cSEMS组和cSEMS+BS组均未报告黄疸病例。cSEMS组基线时平均胆红素水平(μmol/L±标准差)为8.0±4,第10天时为8.5±4.6,而cSEMS+BS组基线时为91.4±108,第10天时为35.3±39(p<0.01)。两组患者在年龄、性别和基线胆红素水平方面相匹配。实验组胆红素血症的变化为+0.98±2.76μmol/L,对照组为+0.39±522μmol/L(p=0.34)。两组在技术成功率、临床疗效、移位及其他并发症方面未观察到显著差异。
对于没有相关胆道梗阻的患者,在内镜下放置覆膜十二指肠支架之前不需要先行胆道支架置入。需要进行前瞻性研究。